Abstract:Background: Systemic sclerosis (SSc) is a chronic and systemic autoimmune disease marked by the skin and visceral fibrosis. Metabolic alterations have been found in SSc patients; however, serum metabolomic profiling has not been thoroughly conducted. Our study aimed to identify alterations in the metabolic profile in both SSc patients before and during treatment, as well as in mouse models of fibrosis. Furthermore, the associations between metabolites and clinical parameters and disease progression were explored. Methods: High-performance liquid chromatography quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF-MS)/MS was performed in the serum of 326 human samples and 33 mouse samples. Human samples were collected from 142 healthy controls (HC), 127 newly diagnosed SSc patients without treatment (SSc baseline), and 57 treated SSc patients (SSc treatment). Mouse serum samples were collected from 11 control mice (NaCl), 11 mice with bleomycin (BLM)-induced fibrosis and 11 mice with hypochlorous acid (HOCl)-induced fibrosis. Both univariate analysis and multivariate analysis (orthogonal partial least-squares discriminate analysis (OPLS-DA)) were conducted to unravel differently expressed metabolites. KEGG pathway enrichment analysis was performed to characterize the dysregulated metabolic pathways in SSc. Associations between metabolites and clinical parameters of SSc patients were identified by Pearson's or Spearman's correlation analysis. Machine learning (ML) algorithms were applied to identify the important metabolites that have the potential to predict the progression of skin fibrosis. Results: The newly diagnosed SSc patients without treatment showed a unique serum metabolic profile compared to HC. Treatment partially corrected the metabolic changes in SSc. Some metabolites (phloretin 2'-O-glucuronide, retinoyl b-glucuronide, all-trans-retinoic acid, and betaine) and metabolic pathways (starch and sucrose metabolism, proline metabolism, androgen and estrogen metabolism, and tryptophan metabolism) were dysregulated in new-onset SSc, but restored upon treatment. Some metabolic changes were associated with treatment response in SSc patients. Metabolic changes observed in SSc patients were mimicked in murine models of SSc, indicating that they may reflect general metabolic changes associated with fibrotic tissue remodeling. Several metabolic changes were associated with SSc clinical parameters. The levels of allysine and all-trans-retinoic acid were negatively correlated, while D-glucuronic acid and hexanoyl carnitine were positively correlated with modified Rodnan skin score (mRSS). In addition, a panel of metabolites including proline betaine, phloretin 2'-O-glucuronide, gamma-linolenic acid and L-cystathionine were associated with the presence of interstitial lung disease (ILD) in SSc. Specific metabolites identified by ML algorithms, such as medicagenic acid 3-O-b-D-glucuronide, 4'-O-methyl-(-)-epicatechin-3'-O-beta-glucuronide, valproic acid glucuronide, have the potential to predict the progression of skin fibrosis. Conclusions: Serum of SSc patients demonstrates profound metabolic changes. Treatment partially restored the metabolic changes in SSc. Moreover, certain metabolic changes were associated with clinical manifestations such as skin fibrosis and ILD, and could predict the progression of skin fibrosis.

Serum Concentrations of Trace Elements/Minerals in Patients with Diffuse Systemic Sclerosis

Trace Element Deficiency in Systemic Sclerosis-Too Much Effort for Some Traces?

Serum Metabolite Differences Detected by HILIC UHPLC-Q-TOF MS in Systemic Sclerosis.

The Association Between Serum Ferritin Levels and Main Systemic Sclerosis Features: A Retrospective Study from a Tertiary Center

Research advancements in the association between prevalent trace metals and connective tissue diseases

Accelerated calciprotein crystallization time (T50) is correlated with impaired lung diffusion capacity in systemic sclerosis

FRI0450 Associations of alterations of peripheral regulatory t and th17 absolute cell numbers with clinical features in patients with systemic sclerosis

Diffusing capacity of lungs for carbon monoxide associated with subclinical myocardial impairment in systemic sclerosis: A cardiac MR study

Oxidative stress markers in blood in systemic sclerosis: A meta-analysis

Serum defensin levels in patients with systemic sclerosis

Serum metabolomic profiling reveals potential biomarkers in systemic sclerosis

Impact of micronutrient deficiency & malnutrition in systemic sclerosis: Cohort study and literature review

Elevated Serum Levels of Interleukin-1Β and Interleukin-33 in Patients with Systemic Sclerosis in Chinese Population

Serum Iron Levels and Copper-to-Zinc Ratio in Sickle Cell Disease

Association between serum KL-6 and SP-D levels and lung function parameters in patients with systemic sclerosis combined with interstitial lung disease

Circulating Collagen Metabolites and the Enhanced Liver Fibrosis (ELF) Score as Fibrosis Markers in Systemic Sclerosis

Serum biomarker-based risk model construction for primary Sjögren's syndrome with interstitial lung disease

The Protective Effect of Hydrogen Sulfide on Systemic Sclerosis Associated Skin and Lung Fibrosis in Mice Model

Analysis of levels of serum trace elements in Crohn′s disease

Changes in peripheral T-lymphocyte subsets and serum cytokines in patients with systemic sclerosis

Metabolic fingerprinting of systemic sclerosis: a systematic review